Ulcerative colitis
Conditions
Interventions
normal dosage of 5-ASA (dosage for maintenance therapy) to maximaum dosage of 5-ASA
no optimized therapy
Sponsors
Center for Diagnostic and Therapeutic Endoscopy,Keio University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients have been diagnosed as definitive ulcerative colitis. 2 Patients with clinical remission (Partial Mayo is 0-2) in addition to Endoscopic Mayo score is 1-2. 3 Patients who agree to entry into this study. 4 Patients whose age is equal and more than 20 years-old.
Exclusion criteria
Exclusion criteria: Patients who can not distinct from other colitis, such as infectious colitis. Patients who have any gastrointestinal stenosis. Patients who were changed the dose of 5-ASA, or who received topical enema, or adalimumab within 2 weeks before the entry of study, or who received infliximab within 4 weeks before the entry of study. Patients who received corticosteroids within 4 weeks before the entry of study. Patients who received thiopurine, or tacrolimus, or cyclosporin within 8 weeks before the entry of study. Patients who receive apheresis within 2 weeks before the entry of study. Patients who will have plans to receive surgical treatments within 12 months after the entry of study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of clinical maintenance of remission within 12 months after entry of the study | — |
Countries
Japan
Contacts
Public ContactMakoto Naganuma
School of Medicine, Keio University Center for Diagnostic and Therapeutic Endoscopy
Outcome results
None listed